Did You Miss Out on Nvidia and Micron Technology? This Super Semiconductor Stock Could Soar Over the Next Few Years.

Cohu is targeting a doubling of production capacity at its Malaysian facilities by the end of 2026 as AI-chip demand boosts orders for its semiconductor test and inspection equipment. Wall Street projects 2026 revenue growth of 35% to $612 million, accelerating from 13% in 2025, while Cohu's high-performance-computing sales pipeline rose to $850 million from $750 million earlier in the year. The stock has gained 188% year-to-date, but its valuation remains demanding at 70.5x projected 2026 adjusted EPS of $0.95; consensus expects EPS to nearly double to $1.85 in 2027, reducing the forward P/E to 36.2x.

Analysis

The investable issue is not AI test demand broadly, but whether Cohu converts its qualification-stage opportunities into production-tool orders fast enough to support utilization and margin recovery. Test-and-handler revenue is highly cyclical and customers can defer installations even while semiconductor capex remains elevated; the cited pipeline should be treated as an indicator of commercial interest rather than contracted backlog. Near-term upside requires order intake and book-to-bill to inflect before consensus earnings upgrades, likely over the next 1-3 quarters.

Cohu is more exposed to the heterogeneous back-end test bottleneck than front-end wafer-fab equipment, but it faces formidable incumbents including Advantest, Teradyne, and FormFactor. AI accelerators and HBM raise test intensity, burn-in requirements, and yield sensitivity, yet this also increases customers' reluctance to qualify smaller vendors on mission-critical production lines. The more consequential 6-18 month catalyst would be evidence that Cohu wins repeat production deployments—not merely initial evaluations—at leading outsourced assembly/test and memory customers.

At the valuation embedded in the article's earnings assumptions, the stock is pricing a steep operating-leverage ramp before it is visible in reported results. That creates asymmetric downside if gross margin fails to expand alongside revenue, particularly given Malaysia ramp costs, FX exposure, and the possibility that AI-related test spending shifts toward larger incumbents. A clean falsification signal is two consecutive quarters of weak HPC order conversion, book-to-bill below 1.0x, or 2027 EPS expectations falling materially below the implied growth trajectory.

Key Decisions for Investors

• Do not chase COHU on the promotional narrative. Establish only a small starter long after the next earnings release if HPC orders, backlog, or book-to-bill demonstrate tangible conversion; target a 6-12 month holding period and limit risk with a stop on a material reduction in 2027 EPS guidance.
• Prefer a conditional pair trade: long COHU / short TER or ATEC? Use TER as the liquid proxy only if COHU demonstrates share gains through repeat production wins. The thesis is that Cohu's smaller revenue base creates greater earnings torque; the risk is that Teradyne captures the higher-value AI test content and the spread widens against COHU.
• For core AI exposure, retain NVDA and MU rather than rotate capital into COHU until Cohu provides independently verifiable order and margin data. COHU has higher upside beta but substantially higher execution risk, while NVDA and MU have more direct visibility into accelerator and HBM demand.
• Set an alert around the next two quarterly reports for gross-margin progression and Malaysia-capacity ramp costs. If revenue grows but margin remains flat or declines, treat that as evidence that incremental AI volume is low-margin or ramp-dilutive and avoid the long.